Medical therapy in heart failure - Is polypharmacy necessary?

被引:0
|
作者
Kwok, BWK [1 ]
机构
[1] Natl Heart Ctr, Dept Cardiol, Singapore 168752, Singapore
关键词
mortality; neurohormone; ventricular dysfunction;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The concept of heart failure has undergone several paradigm shifts in the past few decades. Therapeutic targets directed at the heart pump have shifted to circulatory haemodynamics to the current neurohormonal model. Consequently, therapeutic modalities have similarly evolved alongside clinical trials. Successive trials have tested newer drugs in addition to established therapies, resulting in evidence-based treatments necessitating polypharmacy. Optimal heart failure therapy has therefore become increasingly complex. It is only after understanding the precise modes of drug action, as well as the relevance of the design of clinical trials, will physicians hopefully be able to tailor the medical therapy optimally towards the individual patient with heart failure.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 50 条
  • [1] Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure
    Khan, Muhammad Shahzeb
    Singh, Sumitabh
    Segar, Matthew W.
    Usman, Muhammad Shariq
    Keshvani, Neil
    Ambrosy, Andrew P.
    Fiuzat, Mona
    Van Spall, Harriette G. C.
    Fonarow, Gregg C.
    Zannad, Faiez
    Felker, G. Michael
    Januzzi, James L.
    O'Connor, Christopher
    Butler, Javed
    Pandey, Ambarish
    [J]. JACC-HEART FAILURE, 2023, 11 (11) : 1507 - 1517
  • [2] Heart Failure Medical Management in 2020 Searching for the Right Polypharmacy
    Denny, Rachel M.
    Hummel, Scott L.
    [J]. CIRCULATION-HEART FAILURE, 2020, 13 (11) : E007779
  • [3] Heart Failure 2 Medical therapy for chronic heart failure
    Krum, Henry
    Teerlink, John R.
    [J]. LANCET, 2011, 378 (9792): : 713 - 721
  • [4] The problem of polypharmacy in heart failure
    Flesch M.
    Erdmann E.
    [J]. Current Cardiology Reports, 2006, 8 (3) : 217 - 225
  • [5] Polypharmacy in heart failure patients
    Mastromarino V.
    Casenghi M.
    Testa M.
    Gabriele E.
    Coluccia R.
    Rubattu S.
    Volpe M.
    [J]. Current Heart Failure Reports, 2014, 11 (2) : 212 - 219
  • [6] Heart Failure Research and Polypharmacy
    Somberg, John
    [J]. CARDIOLOGY RESEARCH, 2022, 13 (01) : 1 - 1
  • [7] Guideline-directed medical therapy in patients with heart failure with preserved ejection fraction and polypharmacy: Do not be afraid
    Salah, Husam M.
    Fudim, Marat
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (05) : 1139 - 1141
  • [8] INVESTIGATION MEDICAL THERAPY IN HEART FAILURE
    Su, Ming-Jai
    Chang, Wei-Luen
    Lee, An-Sheng
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 97 : S6 - S6
  • [9] Medical therapy of acute heart failure
    Kleber, FX
    [J]. ZEITSCHRIFT FUR KARDIOLOGIE, 1999, 88 (06): : 394 - +
  • [10] Optimal medical therapy for heart failure
    Bukharovich, IF
    Kukin, M
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 2006, 48 (05) : 372 - 385